Core Viewpoint - The Hong Kong stock market has experienced a significant rise in innovative pharmaceuticals, with the Hang Seng Healthcare Index increasing by 102.76% from the beginning of the year to its peak in September, followed by a decline of 19.06% by December 22. Despite this, the company He Yu has seen a remarkable stock price increase of 370.95% this year, driven by the approval of its core product, Pimicotinib, in China [1][2][5]. Group 1: Product Approval and Market Impact - He Yu announced the approval of its drug Beijiemai (Pimicotinib) by the NMPA, marking it as the first systemic treatment for tenosynovial giant cell tumor (TGCT) in China [2][5]. - The approval process for Beijiemai was expedited, receiving priority review in May and being approved within six months after its NDA application was accepted [6][7]. - The drug has shown strong and durable tumor relief efficacy in clinical trials, providing significant evidence for its long-term safety and effectiveness [6][7]. Group 2: Financial and Market Potential - Pimicotinib is expected to generate substantial revenue, with estimates suggesting it could reach peak sales of approximately $1.5 billion globally [8][9]. - The company has secured a lucrative partnership with Merck, which includes an upfront payment of $70 million and potential total transaction value of up to $606 million, reflecting strong confidence in the drug's market potential [7][9]. - The approval of Pimicotinib is anticipated to enhance the company's cash flow, supporting further innovation and development of its oncology pipeline [9][10]. Group 3: Innovation Pipeline and Valuation - He Yu has established a robust pipeline of 22 differentiated innovative drugs, focusing on precision oncology and immunotherapy, with several candidates showing potential for being first-in-class or best-in-class [9][10]. - The company has been actively repurchasing shares, with a total of 39 buybacks this year, indicating a commitment to returning value to shareholders [10]. - Compared to other biopharma companies, He Yu's price-to-sales (P/S) ratio of 13.38 suggests significant upside potential in valuation, especially with the successful commercialization of Pimicotinib [10].

Core Viewpoint - The Hong Kong stock market has experienced a significant rise in innovative pharmaceuticals, with the Hang Seng Healthcare Index increasing by 102.76% from the beginning of the year to its peak in September, followed by a decline of 19.06% by December 22. Despite this, the company He Yu has seen a remarkable stock price increase of 370.95% this year, driven by the approval of its core product, Pimicotinib, in China, marking a critical milestone for the company [1][4]. Group 1: Product Approval and Market Impact - He Yu's Pimicotinib, a first-in-class drug for treating tenosynovial giant cell tumors (TGCT), has received approval from the National Medical Products Administration (NMPA) in China, representing a significant step towards global commercialization [4][5]. - The approval process for Pimicotinib was expedited, with the drug being accepted for priority review in May and receiving approval just over six months later, highlighting the efficiency of He Yu's research and development system [5][6]. - The MANEUVER study presented at the European Society for Medical Oncology (ESMO) demonstrated Pimicotinib's strong and durable tumor relief efficacy, providing critical evidence for its long-term safety and effectiveness [6][7]. Group 2: Financial and Strategic Developments - He Yu has entered a lucrative partnership with Merck, which includes a high upfront payment and potential milestone payments, indicating strong confidence in Pimicotinib's market potential, with total deal value potentially reaching $606 million [6][8]. - The market for TGCT treatment is currently dominated by Pexidartinib, which has significant safety concerns, positioning Pimicotinib as a safer and more effective alternative, with expectations of substantial revenue growth [7][8]. - He Yu's innovative pipeline includes multiple promising candidates, with ongoing developments in various drug candidates that could further enhance the company's market position and revenue streams [8][9]. Group 3: Valuation and Investor Returns - He Yu has been actively repurchasing shares, with a total of 39 buybacks this year, reflecting a commitment to returning value to shareholders while maintaining a low price-to-sales (PS) ratio of 13.38, suggesting significant upside potential compared to peers [9]. - The successful commercialization of Pimicotinib is expected to generate stable revenue and cash flow, supporting further innovation and development within the company [8][9]. - The company is well-positioned to transition into a leading global biopharmaceutical player, leveraging its innovative capabilities and expanding its market presence [9].